ATTRALUS

Attralus Announces Presentation of Clinical Data on AT-01, a Novel Diagnostic for Systemic Amyloidosis, at the 2021 Society of Nuclear Molecular Imaging Meeting

Retrieved on: 
Tuesday, June 15, 2021
Health, Other Health, Radiology, Clinical trials, Pharmaceutical, Cardiology, Biotechnology, Amyloidosis, Branches of biology, Proteins, Amyloid, Transthyretin, Proteopathy, Cardiac amyloidosis, AT-01 Pan-Amyloid Diagnostic, AT-02 PAR Therapeutic, AT-03 PAR Therapeutic, AT-04 PAR Therapeutic, Systemic Amyloidosis, Attralus, AT-01 PAN-AMYLOID DIAGNOSTIC, AT-02 PAR THERAPEUTIC, AT-03 PAR THERAPEUTIC, AT-04 PAR THERAPEUTIC, SYSTEMIC AMYLOIDOSIS, ATTRALUS

An oral presentation and posters described results from a clinical study evaluating AT-01 (124I-p5+14), a novel, radiolabeled, synthetic amyloid-targeting peptide designed for imaging systemic amyloid deposits.

Key Points: 
  • An oral presentation and posters described results from a clinical study evaluating AT-01 (124I-p5+14), a novel, radiolabeled, synthetic amyloid-targeting peptide designed for imaging systemic amyloid deposits.
  • Currently, a definitive diagnosis of systemic amyloidosis is often made following histological evaluation of a tissue biopsy, said Dr. Wall.
  • In addition, this imaging modality may provide further clinical information to help improve patient management and disease understanding.
  • Attralus is a clinical stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis.

Attralus Announces Presentation of Clinical Data on AT-01, a Novel, Potential First-in-Class Diagnostic for Systemic Amyloidosis at the 2021 American College of Cardiology Annual Meeting

Retrieved on: 
Monday, May 17, 2021
Biotechnology, Pharmaceutical, Health, Amyloidosis, Branches of biology, Proteins, Organ systems, Familial amyloid polyneuropathy, Transthyretin, Amyloid, Proteopathy, AA amyloidosis, AT-01 Pan-Amyloid Diagnostic, AT-02 PAR Therapeutic, AT-03 PAR Therapeutic, AT-04 PAR Therapeutic, Systemic Amyloidosis, Attralus, AT-01 PAN-AMYLOID DIAGNOSTIC, AT-02 PAR THERAPEUTIC, AT-03 PAR THERAPEUTIC, AT-04 PAR THERAPEUTIC, SYSTEMIC AMYLOIDOSIS, ATTRALUS

AT-01 is a novel diagnostic that provides the potential to change the treatment paradigm by enabling detection of all types of systemic amyloidosis at all stages of disease.\xe2\x80\x9d\nCurrently, there are no FDA-approved imaging agents as diagnostics for systemic amyloidosis.

Key Points: 
  • AT-01 is a novel diagnostic that provides the potential to change the treatment paradigm by enabling detection of all types of systemic amyloidosis at all stages of disease.\xe2\x80\x9d\nCurrently, there are no FDA-approved imaging agents as diagnostics for systemic amyloidosis.
  • Systemic amyloidosis is significantly underdiagnosed due to low awareness, lack of specific symptoms, and no current disease-specific diagnostics.
  • The two most common forms of systemic amyloidosis are immunoglobulin light-chain (AL) amyloidosis and transthyretin amyloidosis (ATTR).\nAttralus is a clinical stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis.
  • By targeting the universal disease-causing pathology in systemic amyloidosis diseases, PAR therapeutics have the potential to treat and reverse disease in patients with all types and stages of systemic amyloidosis.

Attralus Therapeutics Appoints Mark Timney as CEO and Expands Leadership Team with New Executives

Retrieved on: 
Monday, May 10, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Systemic Amyloidosis, Attralus, SYSTEMIC AMYLOIDOSIS, ATTRALUS

b'Attralus Therapeutics today announced the appointment of Mark Timney as the company\xe2\x80\x99s Chief Executive Officer and a member of its Board of Directors.

Key Points: 
  • b'Attralus Therapeutics today announced the appointment of Mark Timney as the company\xe2\x80\x99s Chief Executive Officer and a member of its Board of Directors.
  • Timney joins Attralus to accelerate clinical development of its product pipeline and expand the company\xe2\x80\x99s business plan.
  • Most recently, Klein served as Vice President of Analytical Development at Nektar Therapeutics and was a member of the leadership team of the company\xe2\x80\x99s Product Development and Manufacturing group.
  • Attralus was founded by scientific experts in the field of amyloidosis and is headquartered in South San Francisco, California.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210510005237/en/\n'